Further processing options

Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients

Saved in:

Published in: Scientific reports 9(2019) Artikel-Nummer 14635, 6 Seiten
Authors and Corporations: Geist, Marcus Julian Peter (Author), Ziesenitz, Victoria C. (Author), Bardenheuer, Hubert J. (Author), Burhenne, Jürgen (Author), Skopp, Gisela (Author), Mikus, Gerd (Author)
Title: Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients/ Marcus J.P. Geist, Victoria C. Ziesenitz, Hubert J. Bardenheuer, Juergen Burhenne, Gisela Skopp & Gerd Mikus
Type of Resource: E-Book Component Part
Language: English
published:
10 October 2019
Series: : Scientific reports, 9(2019) Artikel-Nummer 14635, 6 Seiten
, volume:9
Source: Verbunddaten SWB
Lizenzfreie Online-Ressourcen
Description
Abstract: Transdermal fentanyl is widely used to control pain in cancer patients. The high pharmacokinetic variability of fentanyl is assumed to be due to cytochrome P450 3A-mediated (CYP3A) N-dealkylation to norfentanyl in humans. However, recently published clinical studies question the importance of the described metabolic pathway. In this small study in palliative cancer patients under real-life clinical conditions, the influence of CYP3A on fentanyl variability was investigated. In addition to the determination of midazolam plasma concentration to reveal CYP3A activity, plasma concentrations of fentanyl and its metabolite, norfentanyl, were measured in identical blood samples of 20 patients who participated in an ongoing trial and had been on transdermal fentanyl. Fentanyl, norfentanyl, midazolam, and 1′-OH-midazolam were quantified by liquid chromatography/tandem mass spectrometry. Plasma concentrations of fentanyl and norfentanyl exhibited a large variability. Mean estimated total clearance of fentanyl and mean metabolic clearance of midazolam (as a marker of CYP3A activity) were 75.5 and 36.3 L/h. Both clearances showed a weak correlation and hence a minimal influence of CYP3A on fentanyl elimination.
Item Description: Gesehen am 10.12.2019
Physical Description: 6
ISSN: 2045-2322
DOI: 10.1038/s41598-019-51279-6